BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (clinicaltrials.gov) - Sep 22, 2026 - P2 | N=250 | Active, not recruiting | Sponsor: SCRI Development Innovations, LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|